Paul K. Winner, DO1,2,3,4,5; Peter McAllister, MD6; George Chakhava, MD, PhD7; Jessica Ailani, MD8; Anders Ettrup, PhD9; Mette Krog Josiassen, PhD9; Annika Lindsten, BSc9; Lahar Mehta, MD10; Roger Cady, MD11
doi : 10.1001/jama.2021.7665
JAMA. 2021;325(23):2348-2356
Intravenous eptinezumab, an anti–calcitonin gene-related peptide antibody, is approved for migraine prevention in adults. It has established onset of preventive efficacy on day 1 after infusion.
Juliana H. VanderPluym, MD1,2; Rashmi B. Halker Singh, MD1,2; Meritxell Urtecho, MD1,3; Allison S. Morrow, BA1,3; Tarek Nayfeh, MD1,3; Victor D. Torres Roldan, MD1,3; Magdoleen H. Farah, MBBS1,3; Bashar Hasan, MD1,3; Samer Saadi, MD1,3; Sahrish Shah, MBBS1,3; Rami Abd-Rabu, MBBS1,3; Lubna Daraz, PhD1,3; Larry J. Prokop, MLS4; Mohammad Hassan Murad, MD, MPH1,3; Zhen Wang, PhD1,3,5
doi : 10.1001/jama.2021.7939
JAMA. 2021;325(23):2357-2369
Migraine is common and can be associated with significant morbidity, and several treatment options exist for acute therapy.
Ai-ris Y. Collier, MD1,2,3; Katherine McMahan, MS3; Jingyou Yu, PhD3; Lisa H. Tostanoski, PhD3; Ricardo Aguayo, BS1; Jessica Ansel, NP3; Abishek Chandrashekar, MS3; Shivani Patel, BA3; Esther Apraku Bondzie, BA3; Daniel Sellers, BS3; Julia Barrett, BS3; Owen Sanborn, BS3; Huahua Wan, MS3; Aiquan Chang, BA2,3; Tochi Anioke, BS3; Joseph Nkolola, PhD3; Connor Bradshaw, BS3; Catherine Jacob-Dolan, BS2,3; Jared Feldman, BS2,4; Makda Gebre, MSc2,3; Erica N. Borducchi, PhD3; Jinyan Liu, PhD3; Aaron G. Schmidt, PhD2,4; Todd Suscovich, PhD5; Caitlyn Linde, PhD5; Galit Alter, PhD2,4; Michele R. Hacker, ScD1,2,6; Dan H. Barouch, MD, PhD2,3,4,6
doi : 10.1001/jama.2021.7563
JAMA. 2021;325(23):2370-2380
Pregnant women are at increased risk of morbidity and mortality from COVID-19 but have been excluded from the phase 3 COVID-19 vaccine trials. Data on vaccine safety and immunogenicity in these populations are therefore limited.
Michael Daly, PhD1; Andrew Jones, PhD2; Eric Robinson, PhD3
doi : 10.1001/jama.2021.8246
JAMA. 2021;325(23):2397-2399
Benjamin N. Rome, MD, MPH1; Joshua J. Gagne, PharmD, ScD1,2; Aaron S. Kesselheim, MD, JD, MPH1
doi : 10.1001/jama.2021.6568
JAMA. 2021;325(23):2399-2402
Peter J. Hotez, MD, PhD1,2; K. M. Venkat Narayan, MD3
doi : 10.1001/jama.2021.7439
JAMA. 2021;325(23):2337-2338
Carlos Blanco, MD, PhD1; Melanie M. Wall, PhD2; Mark Olfson, MD, MPH2
doi : 10.1001/jama.2021.6678
JAMA. 2021;325(23):2339-2340
Humayun J. Chaudhry, DO, MS1; Cheryl Walker-McGill, MD, MBA1,2; Victor J. Dzau, MD3
doi : 10.1001/jama.2021.6694
JAMA. 2021;325(23):2341-2342
John W. Beasley, MD1; Richard G. Roberts, MD, JD1; Allan H. Goroll, MD2
doi : 10.1001/jama.2021.6046
JAMA. 2021;325(23):2343-2344
Lakshmi Srinivasan, MBBS, MTR1
doi : 10.1001/jama.2021.8757
JAMA. 2021;325(23):2345
Rebecca Burch, MD1; Melissa Rayhill, MD2
doi : 10.1001/jama.2021.7275
JAMA. 2021;325(23):2346-2347
Georgine Lamvu, MD, MPH1,2; Jorge Carrillo, MD1,2; Chensi Ouyang, MD1,2; Andrea Rapkin, MD3
doi : 10.1001/jama.2021.2631
JAMA. 2021;325(23):2381-2391
Chronic pelvic pain (CPP) is a challenging condition that affects an estimated 26% of the world’s female population. Chronic pelvic pain accounts for 40% of laparoscopies and 12% of hysterectomies in the US annually even though the origin of CPP is not gynecologic in 80% of patients. Both patients and clinicians are often frustrated by a perceived lack of treatments. This review summarizes the evaluation and management of CPP using recommendations from consensus guidelines to facilitate clinical evaluation, treatment, improved care, and more positive patient-clinician interactions.
Jennifer S. R. Mammen, MD, PhD1; Anne R. Cappola, MD, ScM2,3
doi : 10.1001/jama.2020.22196
JAMA. 2021;325(23):2392-2393
Rita Rubin, MA
doi : 10.1001/jama.2021.5086
JAMA. 2021;325(23):2330-2332
Mary Chris Jaklevic, MSJ
doi : 10.1001/jama.2021.8402
JAMA. 2021;325(23):2333-2334
Rebecca Voelker, MSJ
doi : 10.1001/jama.2021.9227
JAMA. 2021;325(23):2336
Rebecca Voelker, MSJ
doi : 10.1001/jama.2021.8898
JAMA. 2021;325(23):2336
Rebecca Voelker, MSJ
doi : 10.1001/jama.2021.9228
JAMA. 2021;325(23):2336
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.8549
JAMA. 2021;325(23):2335
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.9133
JAMA. 2021;325(23):2335
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.9134
JAMA. 2021;325(23):2335
Stela Celaj, MD, PhD1; Themistoklis Kourkoumpetis, MD, MPH2
doi : 10.1001/jama.2021.4502
JAMA. 2021;325(23):2410
David Alter, MD1; David D. Koch, PhD1
doi : 10.1001/jama.2021.6012
JAMA. 2021;325(23):2402
Jairo Moyano, MD, PhD1; Daniela Abondano, MD1; Veronica Echavarria, MD1
doi : 10.1001/jama.2021.6009
JAMA. 2021;325(23):2402-2403
Anshuman Elhence, MD1; Soumya Jagannath Mahapatra, MD1; Pramod Kumar Garg, MD1
doi : 10.1001/jama.2021.6006
JAMA. 2021;325(23):2403
Mark D. Girgis, MD1; Michael A. Mederos, MD1; Howard A. Reber, MD1
doi : 10.1001/jama.2021.6015
JAMA. 2021;325(23):2403-2404
Jeffrey Bien, MD1; Albert Lin, MD, MPH2
doi : 10.1001/jama.2021.6021
JAMA. 2021;325(23):2404-2405
Leah H. Biller, MD1; Deborah Schrag, MD, MPH1
doi : 10.1001/jama.2021.6027
JAMA. 2021;325(23):2405
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟